Demand for menopause hormone therapy has surged in New Zealand in recent years, pushing manufacturers to their limits and forcing Pharmac, the country's drug-funding agency, to temporarily ration supplies. The spike reflects a dramatic reversal in how women and doctors view a treatment that spent two decades in the shadows after a landmark study sparked widespread fear.
The shift began with reassuring long-term data from the Women's Health Initiative trial, originally published in 2002. That initial study had frightened millions of women away from hormone therapy, showing increased risks of breast cancer, stroke, and blood clots in women who took combination therapy for five years compared to a placebo. But the trial's 18-year follow-up findings told a different story: overall mortality showed no difference between those who had taken five years of MHT and those who took placebo. Newer research on transdermal estrogen treatments like patches and gels found little to no association with stroke and blood clots—addressing some of the original concerns that had deterred women from seeking relief.
The clinical guidelines have shifted accordingly. Today, body-identical hormones including transdermal estradiol and progesterone capsules represent the standard treatment. The approach has changed from offering therapy only to women with severe symptoms at the lowest possible dose, to offering MHT more broadly after discussing both risks and benefits, with the goal of achieving full symptom relief. Women now know that hormone therapy can relieve hot flushes and night sweats while protecting bone health—a recognition that has sparked genuine demand for better menopause care.
Yet the supply surge has exposed serious gaps in the health system. Many doctors simply lack the training and experience to prescribe and manage MHT effectively. For decades after the 2002 trial results, physicians stopped prescribing hormone therapy and new doctors never learned. Medical schools taught little about menopause. The consequences persist today: four out of ten medical schools in the UK have no mandatory menopause education in their curriculum, and a US survey found that most obstetrics and gynecology training programs lack modules on menopause.
This knowledge gap means some practitioners cannot adequately discuss menopausal symptoms with patients or optimize their treatment. In New Zealand, researchers and clinicians are working to close this divide. They have developed a short online training course on menopause care for nurses, nurse practitioners, and doctors, and are creating new content for medical students. Advocacy continues for expanded, funded MHT options across the country.
Yet significant blind spots remain. New Zealand lacks current data on who is actually using MHT and what women want from their care—information that would help shape a more responsive health system. As demand continues to climb and awareness spreads about menopause as a treatable health condition rather than an inevitable decline, closing both the supply and training gaps has become urgent work.